GKOS - NYSE

Glaukos Corporation

Glaukos Corporation

GKOSยทNYSE

$113.64

+2.6%
HealthcareMedical - Devices

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$6.67B
EPS-3.2800
P/E Ratio-34.65
Earnings Date07/29/2026
Glaukos Corporation

Glaukos Corporation Fair Value Envelope

GKOS ยท NYSE

Our analysis suggests that GKOS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $113.64, this represents a potential HIDDEN relative to our calculated worth for Glaukos Corporation.

HIDDEN
Intrinsic Value
Current Price: $113.64

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$900.5M
+ Cash & Equivalents$90.8M
Firm Value-$809.7M
- Debt$139.6M
Equity Value-$949.3M
/ Shares Outstanding57,406,040B
DCF Value-$17
OVERVALUED BY 115%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$55.7M
-$66.9M
-$80.3M
-$96.5M
-$115.9M
-$139.3M
-$167.3M
-$201.0M
-$241.5M
-$290.1M
Maintenance CapEx
-$1.8M
-$2.2M
-$2.7M
-$3.2M
-$3.8M
-$4.6M
-$5.5M
-$6.7M
-$8.0M
-$9.6M
Owner Earnings
-$57.5M
-$69.1M
-$83.0M
-$99.7M
-$119.8M
-$143.9M
-$172.9M
-$207.6M
-$249.4M
-$299.7M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$53.3M
-$59.2M
-$65.9M
-$73.3M
-$81.5M
-$90.7M
-$100.9M
-$112.2M
-$124.8M
-$138.8M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your GKOS research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.